Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07002905 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities
A Phase 2 study, sponsored by Ascletis Pharma (China) Co., Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT07002905: Completed Phase 2 study, sponsored by Ascletis Pharma (China) Co., Limited.
NCT07002905 is a Phase 2 study that has completed, run by Ascletis Pharma (China) Co., Limited. The registered enrollment target is 125 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07002905, a Phase 2 study, has completed, sponsored by Ascletis Pharma (China) Co., Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled phase IIa study is designed to evaluate the efficacy, safety, and tolerability of ASC30 Tablets and ASC30 Tablets A1.
Interventions
- DRUG ASC30 tablets or ASC30 tablets A1 or placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2025-07-03 |
| Est. Completion | 2025-12-08 |
| Phase | Phase 2 |
What the finished NCT07002905 record still lists
NCT07002905 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which ASC30 tablets or ASC30 tablets A1 or placebo is the first listed.
NCT07002905 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07002905 about?
NCT07002905 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities". This randomized, double-blind, placebo-controlled phase IIa study is designed to evaluate the efficacy, safety, and tolerability of ASC30 Tablets and ASC30 Tablets A1.
What is the current status of trial NCT07002905?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2025-07-03. Estimated completion is 2025-12-08.
What interventions are being tested in trial NCT07002905?
The interventions under investigation include: ASC30 tablets or ASC30 tablets A1 or placebo (DRUG).
Who is sponsoring clinical trial NCT07002905?
This trial is sponsored by Ascletis Pharma (China) Co., Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07002905's enrollment target sits among peer trials
125 558th of 2000 higher than 1,437 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI